Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Sixth Street Specialty Lending explains its plan for navigating volatility to stakeholders (SeekingAlpha) +++ SIXTH STREET SPECIALTY LENDING Aktie +3,90%

ORASURE Aktie

 >ORASURE Aktienkurs 
2.68 EUR    -2.2%    (TradegateBSX)
Ask: 2.62 EUR / 1515 Stück
Bid: 2.56 EUR / 1566 Stück
Tagesumsatz: 4880 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ORASURE Aktie über LYNX handeln
>ORASURE Performance
1 Woche: -0,7%
1 Monat: +16,5%
3 Monate: +27,6%
6 Monate: -3,9%
1 Jahr: -18,0%
laufendes Jahr: +28,8%
>ORASURE Aktie
Name:  ORASURE TECHNOLOGIES
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US68554V1089 / 881351
Symbol/ Ticker:  EP3 (Frankfurt) / OSUR (NASDAQ)
Kürzel:  FRA:EP3, ETR:EP3, EP3:GR, NASDAQ:OSUR
Index:  -
Webseite:  https://orasure.com/
Profil:  Orasure Technologies Inc. is a biotechnology company primarily focused on developing point-of-care diagnostic testing and specimen collection devices. Known for its innovation in oral fluid diagnostic..
>Volltext..
Marktkapitalisierung:  187.47 Mio. EUR
Unternehmenswert:  53.09 Mio. EUR
Umsatz:  99.66 Mio. EUR
EBITDA:  -52.23 Mio. EUR
Nettogewinn:  -59.55 Mio. EUR
Gewinn je Aktie:  -0.81 EUR
Schulden:  35.45 Mio. EUR
Liquide Mittel:  172.66 Mio. EUR
Operativer Cashflow:  -42.48 Mio. EUR
Bargeldquote:  5.01
Umsatzwachstum:  -45.44%
Gewinnwachstum:  -210.67%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  2 Insider kauften innerhalb der letzten 30 Tage Aktien im Wert von 132.063 USD.
Suchwörter:  ORASURE
Letzte Datenerhebung:  18.03.26
>ORASURE Kennzahlen
Aktien/ Unternehmen:
Aktien: 69.13 Mio. St.
Frei handelbar: 94.3%
Rückkaufquote: 6.95%
Mitarbeiter: 501
Umsatz/Mitarb.: 0.2 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 60.57%
Bewertung:
KGV: -
KGV lG: -
KUV: 1.93
KBV: 0.64
PEG-Ratio: -0.01
EV/EBITDA: -
Rentabilität:
Bruttomarge: 38.18%
Gewinnmarge: -59.76%
Operative Marge: -59.23%
Managementeffizenz:
Gesamtkaprendite: -15.57%
Eigenkaprendite: -18.3%
>ORASURE Peer Group
Gesundheit, AIDS/ HIV- Behandlung
 
18.03.26 - 01:42
Altai Capital presses OraSure to sell and give it board seats, letter says (Reuters EN)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
17.03.26 - 21:54
OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital (GlobeNewswire EN)
 
OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital...
17.03.26 - 16:48
Activist Altai Capital pushes for OraSure sale, board seats (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.03.26 - 14:18
Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance (Business Wire)
 
Calls on Company to Reach a Fair Settlement that Appoints Altai Nominees Rishi Bajaj and John Bertrand to the BoardLOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the “Board”) outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. In the letter, Altai calls on the OraSure Board to reach a fair settlement that results in the appointment of Altai's highly-qualified director nominees, Rishi Bajaj and John Bertrand, to the Board. Highlights of the letter, which can be found in full here, include: Chronic Underperformance. OraSure's share price has dramatically underperformed comparable companies and broader indices over both five- and ten-year period...
17.03.26 - 05:01
Insiderhandel: Chief Financial Officer kauft Aktien von OraSure Technologies im Wert von 66030 USD (Insiderkauf)
 
Mcgrath, Kenneth J. - Vorstand - Tag der Transaktion: 2026-03-13...
17.03.26 - 05:01
Insiderhandel: President & CEO kauft Aktien von OraSure Technologies im Wert von 66033 USD (Insiderkauf)
 
Eglinton, Manner Carrie - Vorstand - Tag der Transaktion: 2026-03-13...
26.02.26 - 02:24
OraSure signals revenue ramp in H2 2026 with two FDA-submitted diagnostics launches (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
10.02.26 - 14:09
OraSure to Launch OraQuick™ HIV Self-Test in Canada (GlobeNewswire EN)
 
BETHLEHEM, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its OraQuick™ HIV Self-Test has received a license from Health Canada for use in Canada....
09.02.26 - 22:18
OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th (GlobeNewswire EN)
 
BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026....
15.01.26 - 19:03
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital (GlobeNewswire EN)
 
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital...
15.01.26 - 14:39
Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors (Business Wire)
 
Reiterates Urgent Need for Change to Address Company's Failure to Deliver Value to ShareholdersLOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has nominated two highly-qualified candidates, John Bertrand, Co-Founder of Digital Diagnostics, and Rishi Bajaj, President and CIO of Altai, for election to the OraSure Board of Directors (the “Board”) at the 2026 Annual Meeting of Stockholders. The nomination follows Altai's December 17 letter to the Board outlining its serious concerns about the Company's significant share price underperformance driven by poor strategic and capital allocation decisions by management and the Board's refusal to consider alternative strategies for value creation. “As long-term OraSure shareholders, we remain firmly convinced in...
06.01.26 - 19:00
OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device (Zacks)
 
OSUR files FDA applications seeking approval for two at-home STI tests, advancing decentralized diagnostics; shares gain 3.8% as it targets long-term growth....
05.01.26 - 14:03
OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review (GlobeNewswire EN)
 
OraSure Submits CT/NG Molecular Self-Test and Colli-Pee Urine Collection Device for FDA Review...
17.12.25 - 19:27
OraSure Technologies Issues Statement Regarding Altai Capital′s Intent to Nominate Director Candidates (GlobeNewswire EN)
 
OraSure Technologies Issues Statement Regarding Altai Capital's Intent to Nominate Director Candidates...
17.12.25 - 14:48
Altai Capital plans to nominate two directors to OraSure′s board (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.12.25 - 14:06
Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors (Business Wire)
 
Issues Letter Outlining Company's Failure to Deliver Value to Shareholders LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. (“Altai”), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter notifying the OraSure Board of Directors (the “Board”) of Altai's intention to nominate two highly-qualified candidates, John Bertrand, CEO of Digital Diagnostics, and Rishi Bajaj, President and CIO of Altai, for election to the Board at the upcoming 2026 Annual Meeting of Stockholders. The intention to nominate these candidates comes in response to OraSure's significant share price underperformance driven by poor strategic and capital allocation decisions and the Board's refusal to consider alternative strategies for value creation. As long-term shareholders motivated to drive change, Altai believes these candidate...
03.12.25 - 01:01
Insiderhandel: Aufsichtsrat kauft Aktien von OraSure Technologies im Wert von 4982 USD (Insiderkauf)
 
Gagliano, Nancy J. - Aufsichtsrat - Tag der Transaktion: 2025-11-28...
19.11.25 - 19:48
OraSure stellt auf Investorenkonferenz strategisches Wachstum und Innovation in den Fokus (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
17.11.25 - 13:48
OraSure to Participate in Upcoming Investor Conference (GlobeNewswire EN)
 
OraSure to Participate in Upcoming Investor Conference...
06.11.25 - 02:31
OraSure Technologies (OSUR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
 
OraSure (OSUR) delivered earnings and revenue surprises of +18.75% and -7.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: In Fährden ist das höchste Gut die Kühnheit. - In rebus dubiis plurimi est audacia. - Publilius Syrus
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!